Test Price
7,000 AED✅ Home Collection Available
Oncomine Tumor Mutation Burden (TMB) & Microsatellite Instability (MSI) Analysis in UAE | 7000 AED | 2026 DHA Guidelines
تحليل Oncomine Tumor Mutation Burden (TMB) و Microsatellite Instability (MSI) في الإمارات | ٧٠٠٠ درهم | معتمد من هيئة الصحة بدبي
Executive Summary – الخلاصة التنفيذية
Guaranteed Accuracy: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited NGS+Sanger sequencing.
Premium Logistics: Paid Hospital-Grade Home Collection with ISO Certified Cold-Chain transport & VIP Mobile Phlebotomy (8 AM‑11 PM).
Clinical Guidance: Complimentary telephonic post‑test interpretation with a clinical genomics specialist.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
يقدم هذا التحليل الجيني المتطور تقييمًا دقيقًا لعبء الطفرات الورمية وعدم استقرار السواتل الدقيقة مستخدمًا تقنية التسلسل الجيني فائقة الدقة (NGS) ومؤكدًا بطريقة سانجر، مما يوجه قرارات العلاج المناعي والموجه بدقة متناهية.
Compliant with Federal Decree‑Law No. 41 of 2024 (Art. 87), CDS Law 2026 (Minors), and UAE PDPL. ISO 9001:2015 Cert: INT/EGQ/2509DA/3139. Facility License: 9834453.
Overview
The Oncomine TMB & MSI Analysis is a comprehensive next‑generation sequencing test that quantifies tumor mutational burden and microsatellite instability status from tumor tissue and blood, guiding immunotherapy and targeted therapy decisions.
يُعد تحليل Oncomine TMB و MSI من الاختبارات الجينية المتطورة التي تحدد عبء الطفرات الورمية وحالة عدم استقرار السواتل الدقيقة من أنسجة الورم والدم، مما يوجه قرارات العلاج المناعي والموجه.
| Feature | Our Test – TMB+MSI NGS Panel | Closest Alternative (Standard PCR‑Based MSI) |
|---|---|---|
| Precision | High‑throughput NGS with orthogonal Sanger validation; detects low‑frequency variants | PCR‑based, limited to pre‑defined microsatellite markers; missing rare instability patterns |
| Methodology | Next‑Generation Sequencing (NGS) + Sanger Sequencing confirmation | PCR fragment analysis |
| Turnaround Time | 2–3 weeks | 4–6 weeks |
| Actionable Insights | Simultaneous TMB (mut/Mb) + MSI status; correlates with ICI response across tumor types | Only MSI‑H/dMMR status; no TMB data |
Physician Insight & Safety Protocol
“As an oncologist, I understand that awaiting genomic testing can be anxiety‑inducing. This test provides critical insights into your tumor’s behavior, but it must be interpreted within the full clinical picture. Please discuss the results with your treating physician before making any treatment changes.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011, Consultant Medical Oncologist
Medication Warning
Do not discontinue any prescribed medication without consulting your doctor. Test results alone are not a substitute for a full clinical assessment.
Exclusion Criteria & Emergency Red Flags
- Prescription Requirement: This test must be ordered by a licensed physician. Prescription is not applicable for surgery clearance, pregnancy‑related decisions, or travel abroad.
- Sample Adequacy: Requires suitable tumor tissue (biopsy/resection) and paired peripheral blood; samples with necrosis > 30% may be rejected.
- ER Red Flags: If you experience severe pain, bleeding at biopsy site, or sudden clinical deterioration, seek emergency care immediately. Do not wait for genetic test results.
- Pregnancy & Paediatrics: Not validated for foetal testing or minors without explicit paediatric oncology consultation (CDS Law 2026).
Patient FAQ & Clinical Guidance
1. What is the purpose of TMB & MSI testing?
Snippet: TMB and MSI testing identifies tumor genomic instability, predicting response to immune checkpoint inhibitors like pembrolizumab.
يهدف تحليل TMB و MSI إلى تحديد عدم الاستقرار الجيني للورم للتنبؤ باستجابة العلاج المناعي مثل مثبطات نقاط التفتيش المناعية.
2. How is the test performed and what is the turnaround time?
Snippet: The test uses Next‑Generation Sequencing on tumor biopsy and a blood sample, requiring 2–3 weeks for complete analysis.
يُجرى الاختبار بتقنية التسلسل الجيني (NGS) على خزعة الورم وعينة الدم ويستغرق من 2 إلى 3 أسابيع لإتمام التحليل الشامل.
3. Is this covered by insurance in the UAE?
Snippet: Many UAE insurers cover TMB/MSI testing for approved cancer types; we offer direct billing verification via WhatsApp.
تغطي شركات التأمين في الإمارات تحليل TMB/MSI لأنواع السرطان المعتمدة، ونوفر التحقق المباشر من التغطية عبر واتساب.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians